# Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)

> **NCT01947959** · — · COMPLETED · sponsor: **Bayer** · enrollment: 665533 (actual)

## Conditions studied

- Venous Thrombosis
- Pulmonary Embolism
- Atrial Fibrillation
- Acute Coronary Syndrome

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, Bay59-7939)
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT01947959
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-22
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 665533 (ACTUAL)
- **Last updated:** 2021-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01947959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01947959, "Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01947959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*